research update

  • Research updates, November 11

    Research updates, November 11

    The RECOVER-NEURO clinical trial found that “cognitive rehabilitation” failed in treating Long COVID. The National Institutes of Health (NIH) study included 328 people who underwent interventions of either online cognitive training (computer games), a cognitive rehabilitation program, or received electric currents on their heads.

  • Research updates, November 4

    Research updates, November 4

    The German government is cutting millions of euros in Long COVID funding, according to the German business newspaper Handelsblatt.

  • Research updates, October 28

    Research updates, October 28

    A small mechanistic study in Frontiers in Immunology analyzed chronic inflammation in COVID-19. Researchers assessed over 70,000 blood cells from eight participants across different disease states.

  • Research updates, October 21

    Research updates, October 21

    A clinical trial for the anti-inflammatory drug Colchicine did not find the drug effective for Long COVID, according to a new study published in JAMA Internal Medicine. The randomized trial included 346 participants in India who took at least 0.5 milligrams once or twice per day, or a placebo, for 52 weeks.

  • Research updates, October 14

    Research updates, October 14

    A large electronic health records study found SARS-CoV-2 infection is associated with elevated risks of Human Papillomavirus (HPV)-related cancer.

  • Research updates, October 7

    Research updates, October 7

    A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week.

  • Research updates, September 30

    Research updates, September 30

    Researchers in Spain assessed over 190,000 participants, using data from a public health research network, in a study published in the journal Vaccines. They found that Long COVID prevalence was three to 10 times higher in individuals with three or more reported infections than in those with only one infection.

  • Research updates, September 23

    Research updates, September 23

    Two recent studies found limitations of the drug Paxlovid for protection from Long COVID, contrasting prior studies that suggested the antiviral drug might help prevent this disease.

  • Research updates, September 16

    Research updates, September 16

    An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced Long COVID, according to a new systematic review that synthesized over 400 studies.

  • Research updates, September 9

    Research updates, September 9

    A large study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed Long COVID. “This finding is consistent with the higher prevalence estimates reported globally and highlights the long-term burden of post-acute COVID-19 symptoms,” the authors of the study, published in BMC Infectious Diseases, wrote.

get the latest long covid news

Processing…
Success! You're on the list.
SpotifyApple PodcastsPocketCastsAmazon MusiciHeartRadio